Myaware – UK charity dedicated to the care and support of people affected by myasthenia – will be hosting a Zoom session on Research and Treatment regarding Congenital Myasthenia Syndrome (CMS) with Dr Sithara Ramdas, Consultant Paediatric Neurologist. Dr Ramdas is based at the John Radcliffe Hospital in Oxford and has extensive experience working with […]
Welcome to the MDI website. Content and updating of information is ongoing on our website, therefore if you cannot find what you are looking for please contact us.
PPI Research
Public and Participant Involvement in Research (PPI) Muscular Dystrophy Ireland are inviting people living with neuromuscular conditions, their carers, and their families, to join a panel of PPI contributors. The purpose of the PPI panel is to support research and researchers seeking new treatments and therapies for neuromuscular conditions. This is an opportunity for people […]
Webinar: Gene Therapy Clinical Update
Parent Project Muscular Dystrophy has invited Sarepta Therapeutics to present details of the EMBARK clinical trial (SRP-9001-301). They are hosting a webinar on Wednesday, October 13th at 3 PM EST. PLEASE NOTE: Webinar takes place at 3pm USA Eastern Standard Time which is 8pm IRISH TIME. For more details see: http://join.parentprojectmd.org/site/MessageViewer?em_id=31904.0&dlv_id=26669
Paediatric-focused seminar on spinal muscular atrophy (SMA) from MDUK
Join Muscular Dystrophy UK on Monday 23 August 10am-12pm for their MDUK Muscles Matter 2021 online seminar on spinal muscular atrophy (SMA). The session will be paediatric-focused, with a panel of researchers, paediatric neurologists and physiotherapists. There will be presentations on the latest research into SMA, discussions on how to manage the condition as well […]
Roche pharmaceuticals receives positive CHMP opinion for Evrysdi, the first at home treatment for SMA
Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven effectiveness in adults, children and infants two months and older. Roche pharmaceuticals has recently announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Evrysdi™ […]
